Phaseline

Targets › PPIX

PPIX: drug programs, companies and trials

2 programs from 2 companies in 3 trials: 1 Phase 3, 1 Phase 1, 1 Phase 4; Oncology; next expected readout Dec 2028.

Open in Phaseline: the race on PPIX, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Roma La SapienzaHexvix®
Photosensitizer prodrug that accumulates in malignant bladder tissue; metabolized to proto
PPIXPhase 4Non-muscle-invasive Bladder CancerDec 2028
BiofronteraBF-200 ALA (Ameluz®)
5-aminolevulinic acid (ALA) prodrug; converted to protoporphyrin IX (PPIX) for photodynami
PPIXPhase 3Superficial Basal Cell Carcinoma; Locally Advanced Colorectal CarcinomaFeb 2029

Conditions

Superficial Basal Cell Carcinoma (1) Locally Advanced Colorectal Carcinoma (1) Non-muscle-invasive Bladder Cancer (1)

Modalities

small molecule (1)

Companies

Biofrontera (1) University of Roma La Sapienza (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.